Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Eberswalde – page 50

1 792 clinical trials in Eberswalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Eberswalde at a glance
1 792
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 792 trials in Eberswalde

Open in trial search

Study on the Effectiveness and Safety of Treprostinil and Drug Combination for Patients with Pulmonary Arterial Hypertension (Group I)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Study on Early Sedation with Dexmedetomidine vs. Placebo for Older Critically Ill Patients on Ventilators

Registered drug
Countries:GermanyGermany
  • Participants:65+ years
  • Sponsor:Monash University

Study on the Effects of Metreleptin for Patients with Partial Lipodystrophy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Metreleptin
  • Sponsor:Chiesi Farmaceutici S.p.A.

Dementia+5

Recruiting

Study on the Benefits of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) for Patients with Various Types of Dementia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.

Study on Zanubrutinib, Tislelizumab, and Sonrotoclax for Patients with Richter Transformation (a type of lymphoma)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonrotoclax
  • Sponsor:University Of Cologne

Long-Term Safety Study of NTLA-2002 for Patients with Hereditary Angioedema, Using Messenger RNA Encoding Cas9 and HU-G012267

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lonvoguran
  • Sponsor:Intellia Therapeutics Inc.

Study of Anifrolumab for Children and Teens with Moderate to Severe Lupus

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Study of Venetoclax, Ibrutinib, and Rituximab or Bendamustine Combination for Patients with Untreated Mantle Cell Lymphoma Not Suitable for High-Dose Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Study on Venetoclax and Obinutuzumab for Adults with Recurring Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Eberswalde

What the registry says about research in the country

01 Hematologic Oncology

Clinical research focusing on Diffuse Large B-Cell Lymphoma (DLBCL) and its various subtypes, evaluating innovative combination therapies for elderly patients.

  • Treatment optimization for older adults
  • B-cell lymphoma variants
  • Targeted therapy combinations

The study explores the effectiveness of combining acalabrutinib with standard lymphoma treatments to improve outcomes in patients over 60 and 80 years of age.

02 Specialized Lymphoma Research

Investigation of multiple B-cell lymphoma subtypes, including rare variants such as primary cutaneous, intravascular, and mediastinal forms.

  • Novel therapeutic approaches
  • Rare lymphoma variants
  • Treatment response assessment

Research aims to enhance progression-free survival through targeted therapeutic strategies.

03 Personalized Medicine

Advancing treatment protocols for elderly lymphoma patients with focus on reduced-intensity therapy combinations.

  • Age-adapted treatments
  • Quality of life considerations
  • Therapeutic efficacy

Studies evaluate modified treatment regimens designed specifically for older adults who cannot tolerate standard intensive therapies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.